+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drugs In Development, 2021

  • ID: 5359619
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 176 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • C4 Therapeutics Inc
  • ConverGene LLC
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription.

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 43 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 7, 17 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Dermatology, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Genito Urinary System and Sex Hormones and Immunology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Ovarian Cancer, Myelofibrosis, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Pancreatic Cancer, Small-Cell Lung Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Lung Cancer, Lymphoma, Non-Hodgkin Lymphoma, Atopic Dermatitis (Atopic Eczema), Breast Cancer, Colon Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Follicular Lymphoma, Hematological Tumor, Leukemia, Myeloproliferative Disorders, Neuroblastoma, Non-Small Cell Lung Cancer, Peritoneal Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Advanced Malignancy, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Cervical Cancer, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Cognitive Disorders, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Coronavirus Disease 2019 (COVID-19), Fabry Disease, Facioscapulohumeral Muscular Dystrophy (FSHD), Fibrosis, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Malignant Mesothelioma, Mantle Cell Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Primary Mediastinal B-Cell Lymphoma, Psoriasis, Pulmonary Arterial Hypertension, Renal Cell Carcinoma, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma), Unspecified B-Cell Lymphomas, Uterine Cancer, Uveal Melanoma, Vaginal Cancer, Vascular Dementias and Vulvar Cancer.

The latest report Bromodomain Containing Protein 4 - Drugs In Development, 2021, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
  • The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • C4 Therapeutics Inc
  • ConverGene LLC
  • MORE
  • Introduction
  • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Overview
  • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Development
  • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Assessment
  • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in Therapeutics Development
  • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles
  • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Discontinued Products
  • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by AbbVie Inc, 2021
  • Pipeline by Amgen Inc, 2021
  • Pipeline by AstraZeneca Plc, 2021
  • Pipeline by Boehringer Ingelheim International GmbH, 2021
  • Pipeline by Bristol-Myers Squibb Co, 2021
  • Pipeline by Bromodomain Pharmaceuticals Inc, 2021
  • Pipeline by C4 Therapeutics Inc, 2021
  • Pipeline by Checkpoint Therapeutics Inc, 2021
  • Pipeline by Constellation Pharmaceuticals Inc, 2021
  • Pipeline by ConverGene LLC, 2021
  • Pipeline by CSPC Pharmaceutical Group Ltd, 2021
  • Pipeline by Epigene Therapeutics Inc, 2021
  • Pipeline by Kainos Medicine Inc, 2021
  • Pipeline by Ningbo Wenda Pharmaceutical Technology Co Ltd, 2021
  • Pipeline by Nuvation Bio Inc, 2021
  • Pipeline by OHM Oncology, 2021
  • Pipeline by Phio Pharmaceuticals Corp, 2021
  • Pipeline by Plexxikon Inc, 2021
  • Pipeline by Red Glead Discovery AB, 2021
  • Pipeline by Resverlogix Corp, 2021
  • Pipeline by Roivant Sciences Ltd, 2021
  • Pipeline by SignalRx Pharmaceuticals Inc, 2021
  • Pipeline by Zenith Epigenetics Ltd, 2021
  • Dormant Products, 2021
  • Discontinued Products, 2021
  • Discontinued Products, 2021 (Contd..1)
List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • AbbVie Inc
  • Amgen Inc
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Bromodomain Pharmaceuticals Inc
  • C4 Therapeutics Inc
  • Checkpoint Therapeutics Inc
  • Constellation Pharmaceuticals Inc
  • ConverGene LLC
  • CSPC Pharmaceutical Group Ltd
  • Epigene Therapeutics Inc
  • Kainos Medicine Inc
Note: Product cover images may vary from those shown
Adroll
adroll